logo
logo
Medifast, Inc.

Medifast, Inc.

NYSE•MED
CEO: Mr. Daniel R. Chard
セクター: Consumer Cyclical
業種: Personal Products & Services
上場日: 1993-12-30
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States and the Asia-Pacific. The company offers weight loss and weight management plans; and GLP-1 support plans that provide access to GLP-1 medications where clinically appropriate under the OPTAVIA brand name. It provides bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups, as well as provides coaching support along with community, nutrition, and healthy habits, and helps people in their weight loss journey. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.
連絡先情報
100 International Drive, 18th Floor, Baltimore, MD, 21202, United States
410-581-8042
medifastinc.com
時価総額
$118.71M
PER (TTM)
-6.4
39.7
配当利回り
--
52週高値
$16.45
52週安値
$10.10
52週レンジ
11%
順位19Top 5.6%
6.2
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$75.10M+0.00%
直近4四半期の推移

EPS

-$1.65+0.00%
直近4四半期の推移

フリーCF

$0.00+0.00%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Quarterly Net Loss Reported Q3 2025 net loss reached ($2.26M) USD, a (300.3)% drop from $1.13M net income in Q3 2024.
Stockholders Equity Increased Total stockholders' equity grew to $214.7M USD at September 30, 2025, up $4.6M despite period net loss.
Cash Position Strengthened Cash and equivalents totaled $99.5M USD as of September 30, 2025, reflecting an $8.6M increase for nine months.
LifeMD Investment Sale Sale of LifeMD equity generated $3.3M realized gains for nine months, boosting other income significantly.

リスク要因

Revenue Drops Significantly Nine month revenue fell $172.8M USD, or 35.7%, driven by ongoing challenges in client acquisition.
Operations Shifted to Loss Q3 operating loss was ($4.1M) USD, a (293.8)% reversal from $2.1M income year prior.
Gross Profit Margin Shrinks Gross profit margin compressed 590 basis points to 69.5% for Q3 2025 due to fixed cost leverage loss.
Active Coach Base Declines Active earning coaches dropped 35.0% to 19,500 as of September 30, 2025, impacting sales volumes.

見通し

Tailoring GLP-1 Offerings Strategy focuses on distinct programs for clients using GLP-1 medications and those transitioning off them.
Next Generation Products Coming Expect launch of next-generation ingredient product line next year to enhance metabolic health offerings.
Investing In Coach Tools Continuing strategic investment in digital tools and programs like EDGE to maximize coach productivity and reach.

同業比較

売上高 (TTM)

Sleep Number CorporationSNBR
$1.44B
-17.0%
Torrid Holdings Inc.CURV
$1.04B
-7.3%
China Automotive Systems, Inc.CAAS
$725.26M
+16.7%

粗利益率 (最新四半期)

1stdibs.Com, Inc.DIBS
74.3%
+3.4pp
Medifast, Inc.MED
69.4%
-5.9pp
Sleep Number CorporationSNBR
59.9%
-0.9pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
SNBR$205.79M-2.716.4%125.5%
DIBS$184.90M-10.3-18.6%14.5%
EM$147.09M-43.5-0.9%0.2%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-13.4%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月27日
|
EPS:-$0.12
|
売上高:-
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月3日|
    売上高: $89.41M-36.2%
    |
    EPS: $-0.21-310.0%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月4日|
    売上高: $105.56M-37.4%
    |
    EPS: $0.23-130.7%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年4月28日|
    売上高: $115.73M-33.8%
    |
    EPS: $-0.07-109.2%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月18日|
    売上高: $602.46M-43.8%
    |
    EPS: $0.19-97.9%
    予想を上回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月4日|
    売上高: $140.16M-40.6%
    |
    EPS: $0.10-95.3%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月5日|
    売上高: $168.56M-43.1%
    |
    EPS: $-0.75-127.0%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年4月29日|
    売上高: $174.74M-49.9%
    |
    EPS: $0.76-79.3%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月20日|
    売上高: $1.07B-32.9%
    |
    EPS: $9.10-29.0%
    予想を上回る